Clinical Activity of Regn1979, an Anti-Cd20 X Anti-Cd3 Bispecific Antibody (Ab) in Patients (Pts) With (W/) Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-Nhl)

Hematological Oncology - United Kingdom
doi 10.1002/hon.58_2629
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF a PHASE I STUDY

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Cd19/Cd20-Redirected Bispecific Car T Cell Treatment in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Phase Ib Study of Cc-122 in Combination With Obinutuzumab (Ga101): Relapsed or Refractory (R/R) Patients With B-Cell Non-Hodgkin Lymphomas (Nhl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Venetoclax (Ven) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (Nhl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Long-Term Outcome of Patients With Relapsed/Refractory B-Cell Non- Hodgkin Lymphoma Treated With Bispecific Antibody Blinatumomab in a Phase I Trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

A Phase I Trial of 19-28z Car-T Cells Post-High Dose Therapy and Autologous Transplantation (Hdt-Asct) for Relapsed and Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-Nhl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Cd20-TCB (Rg6026), a Novel “2:1” Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Rituximab, Bendamustine and Cytarabine (R-Bac) in Patients With Relapsed-Refractory Aggressive B-Cell Lymphoma

American Journal of Hematology
Hematology
2018English

Real-World Bendamustine Use in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R Dlbcl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy